GTS Securities’s Protagonist Therapeutics PTGX Stock Holding History

GTS Securities’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,416	Closed	-$255K	–	1757
2026 Q1	$255K	Buy	+2,416	New	+$214K	0.01%	1202

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GTS Securities's PTGX Position: Q2 2026 in Review

GTS Securities sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 2,416 shares — an estimated $255K sold.

GTS Securities first reported a position in PTGX in Q1 2026 and held it in 1 quarter. The position peaked at $255K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

GTS Securities reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 2,416 Protagonist Therapeutics shares in Q2 2026, an estimated $255K.
GTS Securities first reported a position in Protagonist Therapeutics in Q1 2026 and held it in 1 quarter.
GTS Securities's Protagonist Therapeutics position peaked at $255K in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.